New pill aims to shrink dangerous liver fat
NCT ID NCT07308548
Summary
This study is testing a new oral medication called HP515 to see if it can safely reduce the amount of fat in the liver of people with non-alcoholic fatty liver disease (NAFLD). About 80 participants will take either the HP515 tablet or a placebo (a dummy pill) for 12 weeks. Researchers will use special MRI scans to measure changes in liver fat and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NAFLD - NON-ALCOHOLIC FATTY LIVER DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua Changgung Hospital
NOT_YET_RECRUITINGBeijing, Beijing Municipality, 102218, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Chengdu Seventh People's Hospital
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.